Company intelligence / Profile preview

Behold.ai

London, England, United Kingdombehold.ai ↗

Ownership: Private
Development stage: Commercial

Overview

Behold.ai’s red dot® AI platform has received regulatory approvals including FDA 510(k) clearance for pneumothorax triage and CE marking for chest X-ray diagnosis. The technology has been deployed across multiple NHS sites in the UK with demonstrated improvements in speed and accuracy of radiology diagnostics. It supports real-time analysis of medical images to assist radiologists by highlighting potential abnormalities such as lung nodules or signs of cancer.

Therapeutic areas: OncologyPulmonology
Modalities: Device (AI-powered diagnostic software)Non-pharmacological therapy (diagnostic support)Platform (AI/ML-based radiology analysis)
Industry: Medical Imaging

Partnerships

Merative (US distribution partner)Apollo Hospital Group (India distribution partner)

Beyond the preview

Go deeper on Behold.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Behold.ai.

Explore the full profile